5月18日 - ** Regeneron（REGN.O）股价在盘前交易中下跌11.3%，报619.70美元
(link) ** 该制药公司周五晚间表示，其实验性药物组合在晚期临床试验中，针对某类皮肤癌的无进展生存期并未显示出相较于默克公司（Merck）的 MRK.N Keytruda具有统计学意义的改善
** 该试验旨在评估候选药物fianlimab与已获批药物Libtayo作为不可切除局部晚期或转移性黑色素瘤患者一线治疗方案的疗效
** 该试验的详细结果将在即将举行的医学会议上公布——REGN
** 补充说明：另一项fianlimab的晚期临床试验正在进行中
** 至少四家券商下调了REGN的目标价
** 截至上一交易日收盘，该股年内累计跌幅达9.5%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.